Buy Recommendation for Aquestive Therapeutics: Promising Prospects for Anaphylm’s Market Launch and Growth

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report) today and set a price target of $10.00.

Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Aquestive Therapeutics’ prospects with their product Anaphylm. The company has completed the submission of a New Drug Application (NDA) for Anaphylm, a non-device-based epinephrine product, which has shown clinical results comparable to existing autoinjectors like EpiPen for treating severe allergic reactions. The FDA is expected to accept the NDA soon, with a decision likely by early 2026. The potential for an advisory committee meeting could further highlight Anaphylm’s benefits, and the process is expected to be less challenging than previous similar products.
Additionally, Aquestive is actively preparing for Anaphylm’s potential U.S. launch in the first quarter of 2026, focusing on optimizing market access and raising awareness through medical forums. The company anticipates that Anaphylm could achieve peak sales exceeding $226 million by 2035, with the launch strategy including a scalable sales force. These factors contribute to Selvaraju’s confidence in the stock’s potential, leading to the reiterated Buy rating and a 12-month price target of $10.

In another report released yesterday, Leerink Partners also reiterated a Buy rating on the stock with a $10.00 price target.